KN-DIOC的开发和验证:一种利用超声、全血细胞计数和癌症抗原125诊断卵巢癌的新型术前诊断指标。

IF 2.2 Q3 ONCOLOGY
World Journal of Oncology Pub Date : 2025-07-08 eCollection Date: 2025-08-01 DOI:10.14740/wjon2595
Sorawit Tongyib, Teerapol Saleewong, Woraphot Chaowawanit
{"title":"KN-DIOC的开发和验证:一种利用超声、全血细胞计数和癌症抗原125诊断卵巢癌的新型术前诊断指标。","authors":"Sorawit Tongyib, Teerapol Saleewong, Woraphot Chaowawanit","doi":"10.14740/wjon2595","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer, particularly epithelial ovarian cancer (EOC), is one of the deadliest gynecological malignancies due to nonspecific early symptoms and late diagnosis. Current diagnostic tools, while useful, often do not account for regional variations in disease presentation, particularly in Asian populations. This study aimed to develop and validate a new preoperative diagnostic index tailored to the Thai population by integrating complete blood count (CBC), tumor markers, and ultrasound features.</p><p><strong>Methods: </strong>This retrospective cohort study included patients with pathologic pelvic or adnexal masses scheduled for surgery at Vajira Hospital from April 2022 to October 2024. Clinical data, CBC, cancer antigen 125 (CA125) levels, and ultrasound findings were analyzed to develop and validate a diagnostic index (KMUTT-NMU Diagnostic Index for Ovarian Cancer (KN-DIOC)). The model's performance was compared against established indices like Risk of Malignancy Index (RMI), Risk of Ovarian Malignancy Algorithm (ROMA), and Rajavithi-Ovarian Cancer Predictive Score (R-OPS) through multivariate logistic regression, focusing on key predictors.</p><p><strong>Results: </strong>The study comprised 195 patients divided into 151 for the development dataset and 44 for the validation dataset. The KN-DIOC showed high discriminative ability with an area under curve (AUC) of 0.866, indicating very good capability in differentiating between benign and malignant ovarian masses. The index achieved a sensitivity of 93.75% and a specificity of 78.57%, demonstrating superior performance to traditional diagnostic tools, especially in the validation dataset.</p><p><strong>Conclusion: </strong>The novel diagnostic index (KN-DIOC), incorporating CBC, ultrasound features, and tumor markers, provides a robust tool for preoperative assessment of ovarian tumors in Thai patients. It offers significant improvements in sensitivity and specificity over existing models, suggesting its potential for broader application in similar settings. This index supports enhanced decision-making in gynecological oncology, potentially leading to better patient outcomes through timely and accurate diagnosis.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 4","pages":"365-374"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339250/pdf/","citationCount":"0","resultStr":"{\"title\":\"Development and Validation of KN-DIOC: A Novel Preoperative Diagnostic Index Using Ultrasound, Complete Blood Count, and Cancer Antigen 125 for Ovarian Cancer.\",\"authors\":\"Sorawit Tongyib, Teerapol Saleewong, Woraphot Chaowawanit\",\"doi\":\"10.14740/wjon2595\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ovarian cancer, particularly epithelial ovarian cancer (EOC), is one of the deadliest gynecological malignancies due to nonspecific early symptoms and late diagnosis. Current diagnostic tools, while useful, often do not account for regional variations in disease presentation, particularly in Asian populations. This study aimed to develop and validate a new preoperative diagnostic index tailored to the Thai population by integrating complete blood count (CBC), tumor markers, and ultrasound features.</p><p><strong>Methods: </strong>This retrospective cohort study included patients with pathologic pelvic or adnexal masses scheduled for surgery at Vajira Hospital from April 2022 to October 2024. Clinical data, CBC, cancer antigen 125 (CA125) levels, and ultrasound findings were analyzed to develop and validate a diagnostic index (KMUTT-NMU Diagnostic Index for Ovarian Cancer (KN-DIOC)). The model's performance was compared against established indices like Risk of Malignancy Index (RMI), Risk of Ovarian Malignancy Algorithm (ROMA), and Rajavithi-Ovarian Cancer Predictive Score (R-OPS) through multivariate logistic regression, focusing on key predictors.</p><p><strong>Results: </strong>The study comprised 195 patients divided into 151 for the development dataset and 44 for the validation dataset. The KN-DIOC showed high discriminative ability with an area under curve (AUC) of 0.866, indicating very good capability in differentiating between benign and malignant ovarian masses. The index achieved a sensitivity of 93.75% and a specificity of 78.57%, demonstrating superior performance to traditional diagnostic tools, especially in the validation dataset.</p><p><strong>Conclusion: </strong>The novel diagnostic index (KN-DIOC), incorporating CBC, ultrasound features, and tumor markers, provides a robust tool for preoperative assessment of ovarian tumors in Thai patients. It offers significant improvements in sensitivity and specificity over existing models, suggesting its potential for broader application in similar settings. This index supports enhanced decision-making in gynecological oncology, potentially leading to better patient outcomes through timely and accurate diagnosis.</p>\",\"PeriodicalId\":46797,\"journal\":{\"name\":\"World Journal of Oncology\",\"volume\":\"16 4\",\"pages\":\"365-374\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339250/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/wjon2595\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon2595","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:卵巢癌,特别是上皮性卵巢癌(EOC),是最致命的妇科恶性肿瘤之一,由于非特异性的早期症状和晚期诊断。目前的诊断工具虽然有用,但往往不能解释疾病表现的区域差异,特别是在亚洲人群中。本研究旨在通过整合全血细胞计数(CBC)、肿瘤标志物和超声特征,开发并验证一种适合泰国人群的新的术前诊断指标。方法:本回顾性队列研究纳入2022年4月至2024年10月在Vajira医院计划手术的病理性盆腔或附件肿块患者。分析临床数据、CBC、癌抗原125 (CA125)水平和超声结果,以制定和验证诊断指数(KMUTT-NMU卵巢癌诊断指数(KN-DIOC))。通过多变量logistic回归,将模型的性能与恶性肿瘤风险指数(RMI)、卵巢恶性肿瘤风险算法(ROMA)和rajavith -卵巢癌预测评分(R-OPS)等既定指标进行比较,重点关注关键预测因子。结果:该研究包括195例患者,其中151例为开发数据集,44例为验证数据集。KN-DIOC鉴别能力强,曲线下面积(AUC)为0.866,对卵巢良恶性肿块有很好的鉴别能力。该指标的灵敏度为93.75%,特异性为78.57%,表现出优于传统诊断工具的性能,特别是在验证数据集中。结论:结合CBC、超声特征和肿瘤标志物的新型诊断指数(KN-DIOC)为泰国卵巢肿瘤患者的术前评估提供了强有力的工具。与现有模型相比,它在敏感性和特异性方面有了显著的改进,这表明它在类似环境中有更广泛的应用潜力。该指数支持增强妇科肿瘤学的决策,通过及时准确的诊断可能导致更好的患者结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development and Validation of KN-DIOC: A Novel Preoperative Diagnostic Index Using Ultrasound, Complete Blood Count, and Cancer Antigen 125 for Ovarian Cancer.

Background: Ovarian cancer, particularly epithelial ovarian cancer (EOC), is one of the deadliest gynecological malignancies due to nonspecific early symptoms and late diagnosis. Current diagnostic tools, while useful, often do not account for regional variations in disease presentation, particularly in Asian populations. This study aimed to develop and validate a new preoperative diagnostic index tailored to the Thai population by integrating complete blood count (CBC), tumor markers, and ultrasound features.

Methods: This retrospective cohort study included patients with pathologic pelvic or adnexal masses scheduled for surgery at Vajira Hospital from April 2022 to October 2024. Clinical data, CBC, cancer antigen 125 (CA125) levels, and ultrasound findings were analyzed to develop and validate a diagnostic index (KMUTT-NMU Diagnostic Index for Ovarian Cancer (KN-DIOC)). The model's performance was compared against established indices like Risk of Malignancy Index (RMI), Risk of Ovarian Malignancy Algorithm (ROMA), and Rajavithi-Ovarian Cancer Predictive Score (R-OPS) through multivariate logistic regression, focusing on key predictors.

Results: The study comprised 195 patients divided into 151 for the development dataset and 44 for the validation dataset. The KN-DIOC showed high discriminative ability with an area under curve (AUC) of 0.866, indicating very good capability in differentiating between benign and malignant ovarian masses. The index achieved a sensitivity of 93.75% and a specificity of 78.57%, demonstrating superior performance to traditional diagnostic tools, especially in the validation dataset.

Conclusion: The novel diagnostic index (KN-DIOC), incorporating CBC, ultrasound features, and tumor markers, provides a robust tool for preoperative assessment of ovarian tumors in Thai patients. It offers significant improvements in sensitivity and specificity over existing models, suggesting its potential for broader application in similar settings. This index supports enhanced decision-making in gynecological oncology, potentially leading to better patient outcomes through timely and accurate diagnosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.10
自引率
15.40%
发文量
37
期刊介绍: World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信